| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22019 |
| Drug |
Defatted powder of Arachis hypogaea L., semen (peanuts) |
| Brand |
Palforzia® |
| Indication |
For the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet. |
| Rapid review commissioned |
01/04/2022 |
| Rapid review completed |
04/05/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Palforzia® compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/05/2022 |
| Pre-submission consultation with Applicant |
22/11/2022 |
| Full submission received from Applicant |
06/01/2023 |
| Preliminary review sent to Applicant |
31/05/2023 |
| NCPE assessment re-commenced |
29/06/2023 |
